Literature DB >> 22846110

'At-risk' for psychosis research: where are we heading?

A Lin, B Nelson, A R Yung.   

Abstract

The 'at-risk' criteria are a useful paradigm for investigating the psychological, neurocognitive, neurobiological and genetic risk factors for psychosis, specifically schizophrenia. To date, the primary outcome of interest in at-risk research has been the development of psychotic disorder, whereby patients are categorized as either having 'transitioned' or 'not transitioned'. Despite the acceptance of this dichotomy, it is important to consider that the threshold at which psychotic symptoms progress from attenuated to frank 'psychotic disorder' is arbitrary and may be incorrect or meaningless in terms of neurobiological and functional changes associated with psychosis. This has implications for clinical care and the search for markers of schizophrenia. We present recent research suggesting that the term 'outcome' needs to be broadened to incorporate non-psychotic diagnoses, functioning and negative symptoms. Shifting the traditional notion of outcome is the future challenge for at-risk research, but the inclusion of outcomes other than psychosis is likely to result in better aetiological models of psychotic illness.

Entities:  

Mesh:

Year:  2012        PMID: 22846110      PMCID: PMC6998237          DOI: 10.1017/S2045796012000388

Source DB:  PubMed          Journal:  Epidemiol Psychiatr Sci        ISSN: 2045-7960            Impact factor:   6.892


  35 in total

1.  Treatment of nonpsychotic relatives of patients with schizophrenia: six case studies.

Authors:  Ming T Tsuang; William S Stone; Sarah I Tarbox; Stephen V Faraone
Journal:  Am J Med Genet       Date:  2002-12-08

2.  The schizophrenia prodrome revisited: a neurodevelopmental perspective.

Authors:  Barbara A Cornblatt; Todd Lencz; Christopher W Smith; Christoph U Correll; Andrea M Auther; Emilie Nakayama
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

3.  Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States.

Authors:  Alison R Yung; Hok Pan Yuen; Patrick D McGorry; Lisa J Phillips; Daniel Kelly; Margaret Dell'Olio; Shona M Francey; Elizabeth M Cosgrave; Eoin Killackey; Carrie Stanford; Katherine Godfrey; Joe Buckby
Journal:  Aust N Z J Psychiatry       Date:  2005 Nov-Dec       Impact factor: 5.744

4.  The relationship of social function to depressive and negative symptoms in individuals at clinical high risk for psychosis.

Authors:  C M Corcoran; D Kimhy; M A Parrilla-Escobar; V L Cressman; A D Stanford; J Thompson; S Ben David; A Crumbley; S Schobel; H Moore; D Malaspina
Journal:  Psychol Med       Date:  2010-05-06       Impact factor: 7.723

5.  Deficit and nondeficit forms of schizophrenia: the concept.

Authors:  W T Carpenter; D W Heinrichs; A M Wagman
Journal:  Am J Psychiatry       Date:  1988-05       Impact factor: 18.112

6.  Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?

Authors:  Alison R Yung; Hok Pan Yuen; Gregor Berger; Shona Francey; Te-Chieh Hung; Barnaby Nelson; Lisa Phillips; Patrick McGorry
Journal:  Schizophr Bull       Date:  2007-04-02       Impact factor: 9.306

7.  Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis.

Authors:  Eva Velthorst; Dorien H Nieman; Hiske E Becker; Reinaud van de Fliert; Peter M Dingemans; Rianne Klaassen; Lieuwe de Haan; Thérèse van Amelsvoort; Don H Linszen
Journal:  Schizophr Res       Date:  2009-03-09       Impact factor: 4.939

Review 8.  Early detection and intervention in the initial prodromal phase of schizophrenia.

Authors:  S Ruhrmann; F Schultze-Lutter; J Klosterkötter
Journal:  Pharmacopsychiatry       Date:  2003-11       Impact factor: 5.788

9.  Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.

Authors:  Patrick D McGorry; Alison R Yung; Lisa J Phillips; Hok Pan Yuen; Shona Francey; Elizabeth M Cosgrave; Dominic Germano; Jenny Bravin; Tony McDonald; Alison Blair; Stephen Adlard; Henry Jackson
Journal:  Arch Gen Psychiatry       Date:  2002-10

10.  Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features.

Authors:  Alison R Yung; Lisa J Phillips; Hok Pan Yuen; Patrick D McGorry
Journal:  Schizophr Res       Date:  2004-04-01       Impact factor: 4.939

View more
  13 in total

1.  'Young people at high risk for psychosis: conceptual framework, research evidence and treatment opportunities'.

Authors:  Antonio Lasalvia; Michele Tansella
Journal:  Epidemiol Psychiatr Sci       Date:  2012-09-11       Impact factor: 6.892

2.  Executive functioning and psychopathological profile in relatives of individuals with deficit v. non-deficit schizophrenia: a pilot study.

Authors:  S Scala; A Lasalvia; L J Seidman; D Cristofalo; C Bonetto; M Ruggeri
Journal:  Epidemiol Psychiatr Sci       Date:  2013-04-02       Impact factor: 6.892

3.  Prisoners at ultra-high-risk for psychosis: a cross-sectional study.

Authors:  M Jarrett; L Valmaggia; J Parrott; A Forrester; T Winton-Brown; H Maguire; D Ndegwa; P McGuire; T K J Craig
Journal:  Epidemiol Psychiatr Sci       Date:  2015-03-03       Impact factor: 6.892

4.  Longitudinal Cognitive Performance in Individuals at Ultrahigh Risk for Psychosis: A 10-year Follow-up.

Authors:  Kelly Allott; Stephen J Wood; Hok Pan Yuen; Alison R Yung; Barnaby Nelson; Warrick J Brewer; Daniela Spiliotacopoulos; Annie Bruxner; Magenta Simmons; Christina Broussard; Sumudu Mallawaarachchi; Christos Pantelis; Patrick D McGorry; Ashleigh Lin
Journal:  Schizophr Bull       Date:  2019-09-11       Impact factor: 9.306

5.  Neuroanatomical Predictors of Functional Outcome in Individuals at Ultra-High Risk for Psychosis.

Authors:  Renate L E P Reniers; Ashleigh Lin; Alison R Yung; Nikolaos Koutsouleris; Barnaby Nelson; Vanessa L Cropley; Dennis Velakoulis; Patrick D McGorry; Christos Pantelis; Stephen J Wood
Journal:  Schizophr Bull       Date:  2017-03-01       Impact factor: 9.306

6.  Four-Year Follow-up of Cognitive Behavioral Therapy in Persons at Ultra-High Risk for Developing Psychosis: The Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial.

Authors:  Helga K Ising; Tamar C Kraan; Judith Rietdijk; Sara Dragt; Rianne M C Klaassen; Nynke Boonstra; Dorien H Nieman; Monique Willebrands-Mendrik; David P G van den Berg; Don H Linszen; Lex Wunderink; Wim Veling; Filip Smit; Mark van der Gaag
Journal:  Schizophr Bull       Date:  2016-03-18       Impact factor: 9.306

7.  Predictive validity of conversion from the clinical high risk syndrome to frank psychosis.

Authors:  Laura A Yoviene Sykes; Maria Ferrara; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Diana O Perkins; Daniel H Mathalon; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Thomas H McGlashan; Kristen A Woodberry; Albert R Powers; Allison N Ponce; John D Cahill; Jessica M Pollard; Vinod H Srihari; Scott W Woods
Journal:  Schizophr Res       Date:  2019-12-19       Impact factor: 4.939

8.  Use of the Theory of Planned Behaviour to assess factors influencing the identification of students at clinical high-risk for psychosis in 16+ Education.

Authors:  Debra A Russo; Jan Stochl; Michelle Painter; Gillian F Shelley; Peter B Jones; Jesus Perez
Journal:  BMC Health Serv Res       Date:  2015-09-23       Impact factor: 2.655

9.  Specificity of childhood psychotic symptoms for predicting schizophrenia by 38 years of age: a birth cohort study.

Authors:  H L Fisher; A Caspi; R Poulton; M H Meier; R Houts; H Harrington; L Arseneault; T E Moffitt
Journal:  Psychol Med       Date:  2013-01-10       Impact factor: 7.723

10.  Functional outcome in people at high risk for psychosis predicted by thalamic glutamate levels and prefronto-striatal activation.

Authors:  Paul Allen; Christopher A Chaddock; Alice Egerton; Oliver D Howes; Gareth Barker; Ilaria Bonoldi; Paolo Fusar-Poli; Robin Murray; Philip McGuire
Journal:  Schizophr Bull       Date:  2014-08-14       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.